Source: International Congress 2017 – State of the art session: "Respiratory infections"
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Payam Nahid (San Francisco, United States of America). Anti-tuberculosis drugs. International Congress 2017 – State of the art session: "Respiratory infections"

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Drug resistant pattern of antitubercular drugs in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Availability of anti-tuberculosis drugs in Europe Source: Eur Respir J 2012; 40: 500-503 Year: 2012 Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Cardiotoxicity of a complex of anti-tuberculosis drugs with the inclusion of fluoroquinolones and bedaquiline in an experiment on rats Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021 Drugs anti-inflammatories Source: Virtual Congress 2020 – Management Year: 2020 Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy Source: Eur Respir J 2012; 39: 1263-1266 Year: 2012 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 Drugs anti-virals Source: Virtual Congress 2020 – Management Year: 2020 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Rapid oral desensitization to anti-tuberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002 Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021